# **STUDY AUDIT CHECKLIST**

Principal Investigator:		(if different from PI):	
Employee/Student#:	Phone:	Employee/Student#:	Phone:
Email:		Email:	
Department:		Department:	
Campus Address:		Campus Address:	
Co-Investigator(s) (Name & affiliation or "None"):			
Title of Study:			
STUDY STATUS:			
#SUBJECTS ENROLLED	:		
LOCATION OF STUDY:			
ALL SITES PI IS DIRECT	LY RESPONSIBLE		
DATE OF AUDIT:			
AUDITOR:			
☐ 2. Site Ope ☐ 3. Protoco	ory Documentation erations I Compliance d Consent Documentation		
☐ 6. Safety N		ility	



Auditor:	Date:	IRB#				
	REGULATORY DOCUMENTATION					
1. Regulatory Comments:	documents organized, complete, available:	YesNoN/A				
2. Protocol, o Comments:	urrent IRB approved version in study file:	Yes No N/A				
3. Informed (Comments:	Consent Documents (ICD), current IRB-approved version in study file:	Yes No N/A				
4. Parental P Comments:	ermission Documents, current IRB-approved version in study file:	Yes No N/A				
Comments:	cument current IRB-approved version in study file:	Yes No N/A				
6. IDE applica Comments:	ition/approval:	Yes No N/A				
7. Investigate Comments:	or Brochure/Device Manual in study file:	Yes No N/A				

8. IND application/approval: Comments:	Yes	No	□ N/A
9. Food & Drug Administration (FDA) 1571 current, signed, dated, and completed: Comments:	Yes	No	□ N/A
10. All sub-investigators listed on FDA 1572 current, signed, dated, and completed: Comments:	Yes	No	□ N/A
11. All sub-investigators listed on FDA 1572: Comments:	Yes	No	□ N/A
12. Required Curriculum Vitaes (CV) on file (investigators and sub-investigator listed on Comments:	FDA 1572	2): No	□ N/A
13. Clinical laboratory certifications on file: Comments:	Yes	No	□ N/A
14. Laboratory normals on file: Comments:	Yes	□ No	□ N/A

15. Site signature log in study file:	Yes No N/A
Comments:	
16. Subject enrollment screening log in study file:	Yes No N/A
Comments:	
17. Staff training records in study file:	Yes No N/A
Comments:	res NON/A
Comments:	
18. Sponsor correspondence in study file:	☐ Yes ☐ No ☐ N/A
Comments:	
19. Sponsor monitoring log/reports in study file:	Yes No N/A
Comments:	
20. FDA and all study related correspondence in file:	Yes No N/A
Comments:	
Comments.	
24. O self-resident and the self-resident IRR second and self-resident Alfile	
21. Questionnaire/survey/advertisements/current IRB approved version in study file:	☐ Yes ☐ No ☐ N/A
Comments:	
22. All amendments/modifications/addendums to originally approved protocol or ICD i	
	☐ Yes ☐ No ☐ N/A
Comments:	

23. Waiver or modification of consent and authorization (HIPAA) current IRB approved version in study file:				
	Yes		□ N/A	
Comments:	_	_		
24. All correspondence (e.g., letters, e-mail, ect) to and from the IRB on file:				
	Yes	∐ No	N/A	
Comments:				
25. Annual IRB continuing renewal application review obtained:	Yes	No	N/A	
Comments:				
Confinents.				



Auditor:		Date:		IRB#		
SITE OPERATIONS						
1. Documenta Comments:	ation of P.I./Co-P.I. involvement in co	onducting	and supervising study:	Yes	□ No □ N/A	
2 Posnonsihi	litios and tacks dalogated to qualifies	l norconn	alı	□ Vos □	No □N/A	
Comments:	lities and tasks delegated to qualified	a personn	ei.	Yes _		
3. P.I./Co-P.I. Comments:	directly involved in the ICD process:			Yes	No N/A	
4. P.I./Co-P.I. Comments:	or study personnel delegate availabl	e by phor	ne 24 hours/day to study part	cicipants:	Yes	
5. Process in Comments:	place to maintain study subject confi	dentiality	:	Yes	No □ N/A	
6. All investig Comments:	ators and study personnel completed	d required	d research training:	Yes	No □ N/A	



Auditor:	Date:	IRB#					
	DDOTOCOL COMBULANICE						
PROTOCOL COMPLIANCE							
1. Inclusion/E Comments:	xclusion criteria met per IRB approved protocol:	Yes	∐ No	∐ N/A			
_	study treatment/procedures, performed per IRB approved protocol:	Yes	☐ No	□ N/A			
Comments:							
3. Study adm	inistered by IRB authorized personnel only and at approved sites:	Yes	No	□ N/A			
(Look for sign	natures or notes by personnel not on the list, especially in CRFs)						
Comments:							
4 Only IDD no	rate cal approved concernitant treatment or medications administrated	□ Voc	No	□ N/A			
Comments:	rotocol approved concomitant – treatment or medications administered:	Yes	□ №	∐ N/A			
5. Modification Comments:	ons to the study protocol prior to IRB approval or exemption:	Yes	No	☐ N/A			
6. IRB approv	ed study protocol follow-up procedures performed:	Yes	☐ No	□ N/A			
Comments:							
7. Drug, Devi	ce or test article administration errors:	Yes	No	N/A			
Comments:							



Auditor:	Date:	IRB#		
	INFORMED CONSENT DOCUMEN	TATIO	ON	
1. IRB stampe Comments:	ed ICD correct current version used and in study file:	Yes	□ No	□ N/A
2. ICD in each Comments:	patients source document/medical record:	Yes	∐ No	∐ N/A
3. ICD's signe	d, dated and witnessed:	Yes	No	□ N/A
4. Parental po	ermission/authorization document signed, dated and witnessed:	Yes	□ No	□ N/A
5. Assent doc Comments:	ument signed dated and witnessed:	Yes	No	□ N/A
6. Consent pr Comments:	ocess documented in source document/progress notes:	Yes	No	□ N/A
7. Consent of Comments:	otained prior to study procedures/and or screening as applicable:	Yes	No	□ N/A

8. Subject or legally authorized representative provided with a copy of the consent document: Yes No N/A Comments:
9. All additional consent documents signed, dated and witnessed. (e.g., consent to collect/ take/ store, specimens, audio/video images:  Yes No N/A Comments:



Auditor:	Date:	IRB#					
	SUBJECT RECORDS						
1. Subject red Comments:	ords/source documents organized, readable and secured.:	☐ Yes [	No □ N/A				
2. Subject cas	e history documented to include information, data, and observations of so	ubjects cond	dition at time of				
enrollment: Comments:		☐ Yes [	□ No □ N/A				
3. Study even	ts and progress notes on the conditions of the subject throughout particip						
Comments:		Yes _	_ No				
4. Data collec	ted in source documents are also recorded on Case Report forms as appro						
Comments:		Yes	_ No				
5. Direct Data Comments:	entry system is thorough, accurate, complete and captures study events:	Yes	No N/A				

ι
t



Auditor:	Date:	IRB#				
		l				
SAFETY MONITORING						
	Events (AE) reported to the IRB sponsor and appropriate regulatory agenc	y within re	quired	timeline		
requirements	:: 	Yes	No	□ N/A		
Comments:		res	NO	□ IN/A		
2. Serious Ad	verse Events (SAE) followed to resolution, return to baseline, completion, o	or judged a	cceptal			
and Principal	Investigator:	Yes	No	☐ N/A		
Comments:						
3. All adverse	events recorded in subjects record, source document, and CRF or equivalent	ent:				
		Yes	No	□ N/A		
Comments:						
4. All protoco	I deviations reported to the IRB, Sponsor and appropriate regulatory agenc	cy within re	equired	timeline:		
		Yes	☐ No	□ N/A		
Comments:						
5 All Data Sa	fety Monitoring Board (DSMB) reports sent to the IRB:	Yes	No	□ N/A		
Comments:	rety monitoring board (bomb) reports sent to the mb.			☐ 'Y/'\		

6. IRB notified of unanticipated problems involving risk to subjects at site: Comments:	Yes	No	□ N/A
7. All External SAE, Safety Reports and Med Watch-reports submitted to the IRB within i	equired t	imeline:	□ N/A
Comments:			
8. Periodic Progress reports sent to the IRB if applicable: Comments:	Yes	☐ No	□ N/A
O IDD annual of any sharper in records activity as proving the constitution and evided		v	No DN/A
9. IRB approval of any changes in research activity as required by regulations and guidel Comments:	ines: [	Yes	No  N/A
15. All correspondence (e.g., e-mail, letters) to and from the IRB on file: Comments:	Yes	No	□ N/A



Auditor:	Date:	IRB#			
DRUG/DEVICE/TEST ARTICLE ACCOUNTABILITY					
Records of receipt of drug/device/test a Comments:	articles in study file:	☐ Yes ☐ No ☐ N	I/A		
2. All drugs/devices/test articles secured a	and stored properly (i.e. tempe	erature log, light protections, etc. as per	the		
IDDF): Comments:		☐ Yes ☐ No ☐ N/A			
3. Inventory Log – organized, completed, Comments:	available:	Yes No N	I/A		
4. Drug/device/test article name, dosage comments:	strength, and form type:	Yes No N	I/A		
5. Lot number Comments:		Yes No No	I/A		
6. Expiration date: Comments:		Yes No N	I/A		
7. Date and quantity dispensed: Comments:		Yes No N	I/A		

8. Amount transferred/returned/destroyed: Comments:	Yes	No	□ N/A
9. Date and quantity returned by study participant: Comments:	Yes	No	□ N/A
10. Date and quantity returned to sponsor::  Comments:	Yes	No	□ N/A
11. 24 hour emergency telephone number of Sponsor: (Call and see who answers. Is it still the same as the number listed in the IDDF?) Comments:	Yes	No	□ N/A
12. Chain of custody per regulations or protocol: Comments:	Yes	No	□ N/A
13. Drug/device/test article used for protocol purposes only: Comments:	Yes	No	□ N/A
14. Drug/device/test article manual/package insert information in file: Comments:	Yes	No	□ N/A